-
-
The FDA has approved tigecycline, the first of a new class of antimicrobial agents. The drug is a novel parenteral antibiotic that is chemically similar to minocycline. It is active against a wide variety of bacteria that cause complicated intra-abdominal and complicated skin and skin structure infections including methicillin-resistant Staphylococcus aureus (MRSA). Tigecycline is marketed by Wyeth as Tygacil.
-
Women with polycystic ovaries demonstrate a definite rate of worsening glucose tolerance and conversion to type 2 diabetes mellitus.
-
Two recent studies shed further light on the short-term use of parathyroid hormone (PTH) to enhance the treatment of osteoporosis. PTH is approved for use up to 2 years in patients with moderate-to-severe osteoporosis. The anabolic bone formation induced by PTH is largely lost after stopping therapy, but is well maintained by continued therapy with a biphosphonate. PTH may be given continuously or cyclically to enhance bone formation.
-
Symptoms of lower extremity venous disease are directly related to the degrees of visible and functional disease, but may occur even in legs that appear normal.
-
-
-
The on-line home of Contraceptive Technology Update has moved. CTU On-line now can be found on the newly revamped Thomson American Health Consultants web site. The old familiar address is the same: www.contraceptiveupdate.com.
-
If your clinic uses an outside laboratory, do you know what test is used to diagnose herpes simplex virus type-2 (HSV-2), which causes genital herpes? According to a just-published journal article, many U.S. laboratories are using outdated blood tests that often produce false-positive results.
-
The Food & Drug Administration (FDA) is detaining condoms manufactured by Australia-based Ansell Limiteds Surat Thani, Thailand, plant after two lots failed to meet FDA standards. If your family planning clinic carries such Ansell condom brands as LifeStyles, Mates, and Kama Sutra, what does this mean for your facility?